<DOC>
	<DOCNO>NCT02519582</DOCNO>
	<brief_summary>Phase II trial evaluate safety efficacy oral applique niclosamide patient progressive metachronous synchronous metastasis colorectal cancer among previous therapy ( Nikolo ) . Monocentric open-label clinical trial phase II . All patient receive 2 g p.o . niclosamide daily progression ( accord RECIST ) unacceptable toxicity discontinuation study reason .</brief_summary>
	<brief_title>Drug Trial Investigate Safety Efficacy Niclosamide Tablets Patients With Metastases Colorectal Cancer Progressing After Therapy</brief_title>
	<detailed_description>Effectiveness : • effectiveness measure progression-free survival evaluate RECIST ( Response Evaluation Criteria In Solid tumor ) . Overall survival For overall survival , curve estimate use Kaplan-Meier method</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Niclosamide</mesh_term>
	<criteria>Patient metachronous synchronous metastasis colorectal cancer progression standard therapy proven brain metastasis curative option standard therapy available Age &gt; 18 year At least one metastases measurable accord Response Evaluation Criteria In Solid Tumors V 1.1 CT MRI scan old 2 week inclusion trial Lab value within usual border patient group e.g . Neutrophil ≥ 1.5x109/ •Platelets ≥ 100x109/L Leukocytes ≥ 1.0x109/L Hemoglobin ≥ 9.0 g/dL 5.59 mmol/l Bilirubin ≤ 2 x Upper Limit Normal ( ULN ) due Gilbert 's syndrome Aspartate Aminotransferase ≤ 2.5x Upper Limit Normal patient without liver metastasis ≤ 5.0x Upper Limit Normal patient liver metastasis Alanine aminotransferase ≤ 2.5x Upper Limit Normal patient without liver metastasis &lt; 5.0 x Upper Limit Normal patient liver metastasis adequate renal function ( creatinin ≤ 1.5x Upper Limit Normal ) Eastern Cooperative Oncology Group 0 1 EKG without clinical significant abnormalities No malignant disease ( except colorectal cancer ) within last 5 year inclusion trial except adequately treat basal cell carcinoma skin squamous cell carcinoma skin , situ carcinoma cervix . Patients malignant disease history free disease 5 year . No clinical significant heart disease like e.g . Uncontrolled blood pressure Heart failure New York Heart Association grade &gt; 2 Cardiac infarction within last 12 month No know uncontrolled concomitant disease despite treatment like e.g . Chronic obstructive pulmonary disease ( COPD ) Serious infections No known alcohol drug abuse Absence psychological , familial , sociological geographical condition , potentially hamper compliance study protocol followup schedule Patients use adequate birth control measure , study treatment period least 3 month last study treatment . For woman childbearing potential ( WOCBP ) : negative pregnancy test 72 hour application first dose study drug Patients breastfeed must stop breastfeeding first dose study drug restart till 8 week last drug intake . Written inform consent inclusion accord International Conference Harmonisation good clinical practice ( ICH GCP ) national/local regulation Life expectancy &lt; 3 month Participation another interventional study within last 30 day Known hypersensitivity part study drug Pregnancy breastfeed HIV infection oder active hepatitis B/C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>S100A4</keyword>
</DOC>